eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
This is a test
Partager le livre
- 392 pages
- English
- ePUB (adapté aux mobiles)
- Disponible sur iOS et Android
eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
DĂ©tails du livre
Aperçu du livre
Table des matiĂšres
Citations
Ă propos de ce livre
This "patient-oriented" book was written as a meeting ground for practicing clinicians, allied health professionals, and clinical researchers to provide a practical guide for the contemporary assessment and management of patients with heart failure and cardiomyopathy. It revolves around broad patient scenarios to elegantly (or expertly) guide diagnostic and management strategies. Combining the talents of over one-hundred experts in the field, the book also endeavors to challenge the reader with areas of current controversies and opportunities for clinical investigation with the goals of both orienting clinicians and stimulating their research passions.
Key Features
-
- Provides practical guidance based on real-life heart failure scenarios
-
- Discusses both acute and chronic care patient-oriented scenarios
-
- Covers up-to-date and novel concepts in heart failure
-
- Features the perspectives of current debates and controversies in heart failure
-
- Highlights the opportunities for research in this field
Foire aux questions
Comment puis-je résilier mon abonnement ?
Il vous suffit de vous rendre dans la section compte dans paramĂštres et de cliquer sur « RĂ©silier lâabonnement ». Câest aussi simple que cela ! Une fois que vous aurez rĂ©siliĂ© votre abonnement, il restera actif pour le reste de la pĂ©riode pour laquelle vous avez payĂ©. DĂ©couvrez-en plus ici.
Puis-je / comment puis-je télécharger des livres ?
Pour le moment, tous nos livres en format ePub adaptĂ©s aux mobiles peuvent ĂȘtre tĂ©lĂ©chargĂ©s via lâapplication. La plupart de nos PDF sont Ă©galement disponibles en tĂ©lĂ©chargement et les autres seront tĂ©lĂ©chargeables trĂšs prochainement. DĂ©couvrez-en plus ici.
Quelle est la différence entre les formules tarifaires ?
Les deux abonnements vous donnent un accĂšs complet Ă la bibliothĂšque et Ă toutes les fonctionnalitĂ©s de Perlego. Les seules diffĂ©rences sont les tarifs ainsi que la pĂ©riode dâabonnement : avec lâabonnement annuel, vous Ă©conomiserez environ 30 % par rapport Ă 12 mois dâabonnement mensuel.
Quâest-ce que Perlego ?
Nous sommes un service dâabonnement Ă des ouvrages universitaires en ligne, oĂč vous pouvez accĂ©der Ă toute une bibliothĂšque pour un prix infĂ©rieur Ă celui dâun seul livre par mois. Avec plus dâun million de livres sur plus de 1 000 sujets, nous avons ce quâil vous faut ! DĂ©couvrez-en plus ici.
Prenez-vous en charge la synthÚse vocale ?
Recherchez le symbole Ăcouter sur votre prochain livre pour voir si vous pouvez lâĂ©couter. Lâoutil Ăcouter lit le texte Ă haute voix pour vous, en surlignant le passage qui est en cours de lecture. Vous pouvez le mettre sur pause, lâaccĂ©lĂ©rer ou le ralentir. DĂ©couvrez-en plus ici.
Est-ce que Heart Failure est un PDF/ePUB en ligne ?
Oui, vous pouvez accĂ©der Ă Heart Failure par Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler en format PDF et/ou ePUB ainsi quâĂ dâautres livres populaires dans Medicine et Medical Theory, Practice & Reference. Nous disposons de plus dâun million dâouvrages Ă dĂ©couvrir dans notre catalogue.
Informations
Section III
Managing Chronic Heart Failure
DOI: 10.1201/9780429244544-12
Chapter 10 Outpatient Management of Stable Heart Failure with Reduced Ejection Fraction
Chapter 11 Exercise and Rehabilitation in Heart Failure
Chapter 12 The Patient with Ischemic Heart Failure
Chapter 13 The Non-Ischemic HEART FAILURE Patient
Chapter 14 Valvular Heart Disease and Heart Failure
Chapter 15 The Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
Chapter 16 Heart Failure with Recovered Ejection Fraction (HFrecEF) and Heart Failure with Midrange Ejection Fraction (HFmrEF)
Chapter 17 The Advanced HEART FAILURE Patient
Chapter 18 Palliative Care and Advanced Directives in Heart Failure
Chapter 10
OUTPATIENT MANAGEMENT OF STABLE HEART FAILURE WITH REDUCED EJECTION FRACTION
Leah Reid, Jonathan Murrow, Kent Nilsson, and Catherine Marti
DOI: 10.1201/9780429244544-13
Introduction
Although therapies for HF with preserved ejection fraction (HFpEF) are lacking, there are many therapies available to patients with HF with reduced ejection fraction (HFrEF), regardless of symptomatology.1 Careful consideration should be taken at every encounter to evaluate not only volume status but also to optimize guideline-directed medical therapy as well as device therapy. In this chapter, we outline the current therapy available for outpatient management of HFrEF (Table 10.1).
| Starting Dose (mg) | Target Dose (mg) |
Beta-Blockers | ||
Bisoprolol | 1.25 daily | 10 daily |
Carvedilol | 3.125 b.i.d. | 25 b.i.d. for weight <85 kg and 50 b.i.d. for weight â„85 kg |
Metoprolol succinate | 12.5â25 daily | 200 daily |
Angiotensin Receptor Neprilysin Inhibitors | ||
Sacubitril/valsartan | 24/26â49/51 b.i.d. | 97/103 b.i.d. |
Angiotensin-Converting Enzyme Inhibitors | ||
Captopril | 6.25 t.i.d. | 50 t.i.d. |
Enalapril | 2.5 b.i.d. | 10â20 b.i.d. |
Lisinopril | 2.5â5.0 daily | 20â40 daily |
Ramipril | 1.25 daily | 10 daily |
Angiotensin II Receptor Blockers | ||
Candesartan | 4â8 daily | 32 daily |
Losartan | 25â50 daily | 150 daily |
Valsartan | 40 b.i.d. | 160 b.i.d. |
Aldosterone Antagonists | ||
Eplerenone | 25 daily | 50 daily |
Spironolactone | 12.5â25 daily | 25â50 daily |
Sodium-Glucose Cotransporter-2 Inhibitors | ||
Dapagliflozin | 10 daily | 10 daily |
Empagliflozin | 10 daily | 10 daily |
Vasodilators | ||
Hydralazine | 25 t.i.d. | 75 t.i.d. |
Isosorbide dinitrate | 20 t.i.d. | 40 t.i.d. |
Fixed-dose combination isosorbide dinitrate/hydralazine | 20/37.5 (1 tab) t.i.d. | 2 tabs t.i.d. |
Ivabradine | ||
Ivabradine | 2.5â5 b.i.d. | Titrate to heart rate 50â60 beats/min. Maximum dose 7.5 b.i.d. |
Notes: Isosorbide mononitrate is not recommended by current guidelines, which consider either the fixed-dose combination or the separate combination of isosorbide dinitrate and hydralazine as appropriate guideline-directed therapies for heart failure. | ||
Abbreviations: b.i.d. = bis in die (twice daily); t.i.d. = ter in die (three times daily). | ||
Source: Reproduced with permission from: Maddox et al., J Am Coll Cardiol 2021;77:772â810. |
Beta-Blockers
Maladaptive activation of the sympathetic nervous system in HFrEF can lead to worsening congestion, malperfusion, and arrhythmias.2 Blockade of ÎČ-adrenergic receptors has proven in multiple clinical trials to reduce morbidity and mortalityâspecifically with metoprolol succinate and bisoprolol, which selectively block ÎČ-1-receptors, and with carvedilol, which selectively blocks α-1, ÎČ-1 and ÎČ-2 receptors.3
In the landmark Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), patients with HFrEF (ejection fraction [EF] â€35%) and New York Heart Association (NYHA) class IIâIV symptoms had a 34% relative risk reduction in all-cause mortality with bisoprolol therapy vs placebo.4 The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) and carvedilol trials likewise demonstrated reduced risk of death or HF hospitalization (Figure 10.1).5â7 To reduce morbidity and mortality, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Heart Failure Guidelines thus recommend using either bisoprolol, carvedilol, or sustained-release metoprolol succinate for all patients with current or prior symptoms of HFrEF unless contraindicated (class I, level of evidence [LOE]: A). Importantly, the benefit of ÎČ blockers is dose dependent, with lower achieved heart rates associated with improved outcomes, albeit this effect is mostly relevant to patients in sinus rhythm and not among those with atrial fibrillation.8 A network meta-analysis of 21 trials found a mortality benefit of ÎČ blockers vs p...